ClinicalTrials.gg
Status unknownNCT04161001Updated Nov 13, 2019

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

A Phase 3 interventional study of Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug) and Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug) in Hypertension, Dyslipidemia, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 3 under way, none of them phase 3. Hypertension · Daewoong Pharmaceutical Co. LTD..

Planned enrollment
2nd of 10
237 · median 128
Started
2019
with 2 others
Phase 3
5 of 15
none open now
Registered
9th of 15
by date

Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 9th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., or all of them as a file.
02

Study summary

  • the change of sitSBP based on baseline between Treatment arm and control 1 arm [ Time Frame: 8 weeks ]
  • the change of LDL-C based on baseline between Treatment arm and control2 arm [ Time Frame: 8 weeks ]
03

Conditions studied

  • Hypertension, Dyslipidemia
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 to 80 years
  • patients with hypertension and hyperlipidemias

Exclusion criteria

Exclusion Criteria:

  • orthostatic hypotension
  • History of ventricular tachycardia, atrial fibrillation
  • uncontrolled diabetes mellitus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
237 participants (estimated)

Study arms

  • Experimental
    Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe

    co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe

    Drug: Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)

  • Placebo comparator
    Olmesartan, Rosuvastatin, Ezetimibe

    co-administration of Olmesartan and Rosuvastatin, Ezetimibe

    Drug: Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)

  • Placebo comparator
    Amlodpine, Olmesartan

    co-administration of Olmesartan, Amlodipine

    Drug: Amlodipine/Olmesartan 10/40mg (Combination drug)

Interventions

  • DrugAmlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)

    co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)

  • DrugOlmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)

    co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)

  • DrugAmlodipine/Olmesartan 10/40mg (Combination drug)

    co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)

06

What researchers measure

Primary outcomes

  1. the change of MSSBP based on baseline between Treatment arm and control 1 arm

    Time frame: 8 weeks

  2. the change of LDL-C based on baseline between Treatment arm and control2 arm

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Yonsei University Health System, Severance Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Jongwon Ha · Contact82-02-2228-8448
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2019; primary completion for Nov 2021, 24 months later.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 24 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2019
First posted
Nov 13, 2019
StartEst.
Nov 20, 2019
Primary completionEst.
Nov 20, 2021
CompletionEst.
Feb 2, 2022
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04161001
Responsible party
Sponsor
First posted
Nov 13, 2019
Start date
Nov 20, 2019 (estimated)
Primary completion
Nov 20, 2021 (estimated)
Completion
Feb 2, 2022 (estimated)
Last update
Nov 13, 2019

Study contacts

Daewoong clinical
Contact
shj@daewoong.co.kr
+82-2-550-8800 ext. 8800
Hyunju Shin
Contact
shj@daewoong.co.kr

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion